Latest news
{{'2025-06-23T18:36:26Z' | dateFormatFilter}}
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
{{'2025-06-22T19:35:40Z' | dateFormatFilter}}
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
{{'2025-06-22T13:00:45Z' | dateFormatFilter}}
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Our corporate governance practices take into consideration applicable regulations, corporate governance codes and the Novo Nordisk Way.
Find our more about how we manage our business:
See all our financial results from today and back to 2016, including Annual reports, Quarterly company announcements with financial results, investor presentations, financial workbooks as well as the webcast and presentation from the different investor events like Capital Markets Day.
We are committed to providing therapies and innovative injection devices for patients with diabetes, obesity, and other serious chronic conditions, including haemophilia and growth hormone disorder.
Learn more below about our medicines and broad range of devices.
We have nearly a century of expertise working with proteins and peptides. In recent years, we have increased our research technology platforms to include stem cells, RNA interference and genome editing. To realise the full potential of these research technologies, we are pioneering scientific innovation together with our external partners.
Our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions.
Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, haemophilia, growth disorders and non-alcoholic steatohepatitis (NASH).
Browse our entire R&D pipeline by study phase, or select a specific therapy areas
Access and affordability
We will not allow the success of our company to be defined by the steady increase in the number of people living with serious chronic diseases, like type 2 diabetes and obesity. Our success will be defined by the solutions we bring and the health and well-being of the people and communities benefiting from them.
Learn more about our strategy to defeat diabetes.
Environmental responsibility
We are the first pharmaceutical company to use 100% renewable power in all our global production facilities. We are proud but also motivated to go even further. With our Circular for Zero strategy, we are starting a journey to achieve zero environmental impact in all our business activities.
We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases.
We employ more than 64,000 people in 80 offices around the world, and market our products in 170 countries.
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
